转自：智通财经 MACD金叉信号形成，这些股涨势不错！ 【A股限售股解禁一览：97.3亿元市值限售股今日解禁】智通财经1月22日电，Wind数据显示，周四（1 月22日），共有9家公司限售股解禁，合计解禁量为3.0亿股，按最新收盘价计算，合计解禁市值为97.3 亿元。从解禁量来看，超研股份、兴福电子、泰凯英解禁量居前，解禁股数分别为1.5亿股、1.09亿股、 1527.59万股。从解禁市值来看，兴福电子、超研股份、中钨高新解禁市值居前，解禁市值分别为53.08 亿元、35.82亿元、3.45亿元。从解禁股数占总股本比例来看，超研股份、兴福电子、泰凯英解禁比例居 前，解禁比例分别为35.05%、30.38%、6.9%。 ...

Group 1 - The A-share market experienced a collective decline on January 20, with the medical device ETF (562600) falling by 1.30%. However, certain stocks like Hualan Biological (301093) rose by 5.51%, reaching a historical high [1] - On January 20, the National Medical Insurance Administration officially issued guidelines for auxiliary operation projects, standardizing pricing for 37 items and 5 additional charges related to medical technology innovations such as 3D printing and robotic surgery [1] - CITIC Securities anticipates that from 2025 onwards, there will be a significant release of policy dividends in the medical device sector, with innovations like brain-computer interfaces and artificial hearts being included in medical service pricing, thus expanding the application of surgical robots [1] Group 2 - The medical device industry is experiencing robust growth, and the medical device ETF (562600) provides a convenient way to capture growth opportunities, with brain-computer interfaces making up 23.8% of the index it tracks, the highest among listed ETFs [2] - The medical device sector constitutes 89.2% of the ETF, indicating a high concentration that effectively captures growth opportunities in niche markets [2] - Investors can also consider alternative options such as the Huaxia CSI Medical Device ETF Initiated Link A (021250) and Huaxia CSI Medical Device ETF Initiated Link C (021251) for easier investment [2]

Group 1 - The A-share market experienced a collective decline on January 20, with the medical device ETF falling by 1.30%. However, certain companies like Hualan Biological and Aotai Bio saw increases of 5.51% and 2.59% respectively, with Hualan reaching a historical high [1] - On January 20, the National Healthcare Security Administration issued guidelines for auxiliary operation projects, standardizing pricing for 37 items and 5 additional charges related to medical technology innovations such as 3D printing and robotic surgery [1] - CITIC Securities anticipates that from 2025 onwards, there will be a significant release of policy dividends in the medical device sector, with innovations like brain-computer interfaces and artificial hearts being included in medical service pricing, potentially expanding the application of surgical robots [1] Group 2 - The medical device industry is experiencing robust growth, with the medical device ETF tracking the CSI All-Share Medical Device Index, which has a 23.8% allocation to brain-computer interfaces, the highest among listed ETFs [2] - The medical device sector constitutes 89.2% of the ETF, indicating a high concentration that effectively captures growth opportunities in niche markets [2] - Investors can also consider alternative options such as the Huaxia CSI All-Share Medical Device ETF Initiated Link A and C for convenient investment in the sector [2]

Group 1 - The company announced the release of 150,145,467 restricted shares, which accounts for 35.05% of the total share capital [1] - The listing date for the released restricted shares is set for January 22, 2026 [1] - Approximately 144 million shares will be unlocked and available for trading on the same date [1]

中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 中国银河证券股份有限公司（以下简称"银河证券"、"保荐人"）作为 汕头市超声仪器研究所股份有限公司（以下简称"超研股份"、"公司"）首 次公开发行股票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号—创业板上市公司规范运作》《深圳证券交易所上市公司自律 监管指引第13号——保荐业务》等有关规定，对超研股份部分首次公开发行前 已发行股份及首次公开发行战略配售股份上市流通相关事项进行了核查，具体 情况如下： 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1391号）同意注册，公司已 完成首次公开发行人民币普通股（A股）64,249,446股，并于2025年1月22日在深 圳证券交易所创业板上市，发行完成后总股本为428,329,638股，其中有流通限制 或锁定安排的股票数量为373,553,188股，占发行后总股本的87.21%；无流通限制 及锁定安排的 ...

证券代码：301602 证券简称：超研股份 公告编号：2026-001 汕头市超声仪器研究所股份有限公司 关于部分首次公开发行前已发行股份及首次公开发行战略 配售股份上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本次上市流通的限售股属于公司部分首次公开发行前已发行的股份及首次 公开发行战略配售股份，股份数量为 150,145,467 股，占公司总股本比例为 35.05%，限售期为自公司首次公开发行股票并在创业板上市之日起 12 个月，该 部分限售股将于 2026 年 1 月 22 日锁定期届满并上市流通。 公司上市后至本公告披露之日，公司未发生过因股份增发、回购注销及派发 过股票股利或用资本公积金转增股本等导致公司股本数量变动的情形。 特别提示： （一）汕头市超声仪器研究所股份有限公司（以下简称"公司"）本次解除 限售并上市流通的股份为部分首次公开发行前已发行股份和首次公开发行战略 配售股份。 （二）本次解除限售的股东户数为 3 户，解除限售股份数量为 150,145,467 股，占公司总股本比例为 35.05%，其中首次公开发行前已发行 ...

Macro - Key Points - The central bank will lower the re-lending and rediscount rates by 0.25 percentage points starting January 19, 2026, with new rates set at 0.95%, 1.15%, and 1.25% for 3-month, 6-month, and 1-year re-lending respectively, and a rediscount rate of 1.5% [5] - The financing margin ratio for securities trading will increase from 80% to 100% starting January 19, 2026, while existing contracts will maintain the previous 80% requirement [6] - The China Securities Regulatory Commission (CSRC) is investigating Rongbai Technology for misleading statements in a major contract announcement [12] Industry - Key Points - Shenghong Technology expects a net profit increase of 260% to 295% for 2025, projecting profits between 4.16 billion and 4.56 billion yuan, driven by advancements in AI computing technology [13] - Longi Green Energy anticipates a net loss of 6 billion to 6.5 billion yuan for 2025, citing ongoing challenges in the photovoltaic industry due to supply-demand mismatches and intense competition [14] - Tongwei Co. predicts a net loss of approximately 9 billion to 10 billion yuan for 2025, facing significant operational pressures from industry oversupply and rising raw material costs [15] - Zhongke Aerospace has completed its IPO guidance, marking progress for commercial aerospace companies in the capital market [16]

Group 1 - The total market value of shares to be unlocked next week is 46.499 billion yuan, with 39 stocks involved, totaling 3.447 billion shares [5] - Shimao Energy (605028) announced the termination of control change discussions due to disagreements on core terms, with stock resuming trading on January 19, 2026 [2][3] - Shimao Energy focuses on waste-to-energy production, utilizing waste and coal as primary materials to generate steam and electricity [2] Group 2 - The highest market value of unlocked shares next week is from Xingtum Control, with 123 million shares (70.66% of total shares) becoming tradable, valued at 13.13 billion yuan [5][8] - Shanxi Coking Coal follows with 1.037 billion shares unlocking, valued at 6.968 billion yuan, primarily from targeted placement shares [5] - Five stocks have an unlocking ratio exceeding 20%, with Xingtum Control, Longda Co., and Chaoyan Co. leading at 70.66%, 48.78%, and 35.05% respectively [8]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On January 15, 2025, the company's stock price fell by 3.56%, with a trading volume of 83.72 million yuan and a turnover rate of 5.99%, resulting in a total market capitalization of 10.207 billion yuan [1]. - The stock has seen a net outflow of 7.16 million yuan from major investors, indicating a reduction in holdings over the past two days [4][5]. Product and Industry Insights - The company showcased its innovative veterinary medical imaging products at the 97th WVC annual conference, engaging with industry experts and gaining valuable user insights [2]. - The industrial ultrasound products are primarily applied in non-destructive testing for water and electricity engineering, including pipelines and pressure vessels [2][3].

Core Insights - The article highlights the significant investment activities and developments in the LP market, particularly focusing on the growth of funds in the Chaoyang District of Beijing and other regions, emphasizing the importance of capital in fostering innovation and technology-driven industries [5][6][13]. Investment Activities - Chaoyang District has established a robust ecosystem for high-tech enterprises, with 3,649 national high-tech companies and 25 unicorns projected by mid-2025 [5]. - Two new RMB funds, each with a scale of 2 billion yuan, have been launched to invest in AI, advanced manufacturing, and biopharmaceuticals [6][13]. - Huaye Tiancheng's fifth fund raised 1.76 billion yuan, exceeding its initial target of 1.5 billion yuan, with a high market-oriented capital ratio of 80% [8]. - Lakesun Capital's new fund focused on AI and semiconductor industries raised 400 million yuan [9]. - Dongfang Jiafu's sub-fund for small and medium enterprises successfully completed a first close of 1.6 billion yuan, targeting advanced manufacturing and life sciences [10]. - Warburg Pincus raised 3 billion USD for its financial sector fund, exceeding its initial target by 20% [11]. Fund Establishments - The establishment of the Xi'an Semiconductor Industry Development Fund with a capital of 1 billion yuan aims to leverage Xi'an's technological advantages in the semiconductor sector [15]. - The AIC equity investment fund in Xi'an, with a scale of 1 billion yuan, focuses on high-end equipment manufacturing [17]. - The Huazhong Medical Industry Fund, with a scale of 1 billion yuan, targets chemical innovation drugs and high-end medical devices [23]. - The establishment of the "Laoshan Science and Technology Innovation Mother Fund" with a total scale of 3 billion yuan aims to support emerging industries in Qingdao [20]. GP Recruitment - Zhejiang's special merger and acquisition fund is seeking GP partners to enhance its investment ecosystem, focusing on new-generation information technology and advanced manufacturing [27]. - The Shanxi Jinchuang Technology Innovation Fund is recruiting GP partners to support strategic emerging industries in the province [28].